ZX-7101A potently inhibits cap-dependent endonuclease (CEN) in the PA proteins of
influenza A and B viruses. Its pharmacological property is suitable for a single dose to treat and
prevent influenza A and B virus infections.
In preclinical studies, ZX-7101A demonstrated superior efficacy against anti-influenza virus
over Oseltamivir, and comparable efficacy with Xofluza. Not like Xofluza, ZX-7101A showed no food effect on oral bioavailability,
and potentially has better safety and efficacy in the clinic.
Seloxavir Marboxil has been approved for the indication of uncomplicated influenza in adults.